Dr Reddy's gets 30 days to sell 'Olymviq' stock in Novo trademark case

MUMBAI/NEW DELHI, March 29 -- Dr. Reddy's Laboratories will have 30 days to sell existing stock of its semaglutide drug branded "Olymviq" before discontinuing the name, after the Delhi High Court reco... Read More

Novo Nordisk takes Dr. Reddy's to court over Ozempic-like brand name

MUMBAI/NEW DELHI, March 25 -- As semaglutide, the drug behind weight-loss drug Ozempic, goes off-patent in India and cheaper copies flood the market, Novo Nordisk has moved to defend its flagship bran... Read More

Novo Nordisk sues Dr. Reddy's over Ozempic trademark

MUMBAI/NEW DELHI, March 25 -- As semaglutide, the drug behind weight-loss drug Ozempic, goes off-patent in India and cheaper copies flood the market, Novo Nordisk has moved to defend its flagship bran... Read More

Mint Explainer: Why do Indian drug makers challenge global giants' patents?

New Delhi, Jan. 6 -- Hyderabad-based Natco Pharma Ltd has filed a patent revocation suit against innovator Novo Nordisk for its drug semaglutide, the latest salvo in Indian pharma's legal offensives a... Read More